KR20200144849A - Composition for preventing or treating nasal polyp comprising extract of sargassum serratifolium - Google Patents

Abstract

The present invention provides a pharmaceutical composition and a health functional food composition for preventing, alleviating or treating nasal polyp diseases containing a Sargassum serratifolium extract as an active component. In addition, the present invention provides the pharmaceutical composition and the health functional food composition for preventing nasal polyp recurrence containing the Sargassum serratifolium extract as the active component. The Sargassum serratifolium extract according to the present invention has anti-inflammatory activity, thereby being able to effectively prevent, alleviate or treat nasal polyp diseases. In addition, the Sargassum serratifolium extract according to the present invention has antifibrotic activity, thereby being able to effectively prevent recurrence of cost after cost removal surgery.

Description

Composition for preventing or treating nasal polyp disease, comprising extract of sawtooth capillary spot {COMPOSITION FOR PREVENTING OR TREATING NASAL POLYP COMPRISING EXTRACT OF SARGASSUM SERRATIFOLIUM}

The present invention relates to a composition for preventing or treating nasal polyp disease comprising an extract of sawtooth capillary spot.

Nasal polyp or nasal polyp is a protruding structure that secretes mucus inside the nose, and is a benign edema mucosa caused by recurrence and gradual development of local edema of the nasal or sinus mucosa. Most of the nasal polyp mucosa is composed of respiratory epithelium, and the submucosal layer shows severe edema, and it is known that a large number of inflammatory cells, especially eosinophils, infiltrate into the fibrous tissue.

Until now, the exact cause of nasal polyps is not known, but it is a chronic inflammatory disease, and recurrence is common despite various treatment methods. Nasal polyps are formed and grown by the interaction of inflammatory cells due to infection or non-infectious inflammation. The influx of eosinophils is promoted by various inflammatory mediators secreted from mast cells, and tissue damage is caused by various chemical mediators secreted from eosinophils, which worsens, leading to edema.

Nasal polyps are known to be more common in people with asthma or rhinitis, where the mucous membranes around the nose and throat are inflamed. Symptoms of nasal polyps develop slowly over several months, and the severity of symptoms is determined by the number and size of the polyps. If the size of the nasal polyp is small, there are no specific symptoms, but various symptoms may appear as the size increases gradually. The main symptoms of nasal polyp are persistent nasal mucus secretion, nasal congestion caused by polyps, and decreased sensation of smell. In some cases, obstructive nasal sounds may be complained, and in very severe cases, anatomical changes may occur, leading to a wider nose.

The purpose of treatment of nasal polyps is to eliminate symptoms caused by nasal polyps, to restore nasal function as a respiratory tract by removing nasal polyps, and to induce drainage and ventilation of the sinuses. In addition, the purpose of treatment is to restore smell and prevent recurrence of nasal polyps. Treatment of nasal polyps can be largely divided into drug therapy and surgical therapy. Currently, the use of steroids as drug therapy is known to be effective in treating nasal polyps. In order to alleviate runny nose and nasal congestion, there is a drug therapy that reduces polyps by spraying steroids into the nose or by injecting steroids directly into the polyp. In the case of large polyps, it is removed by surgery, which is called polypectomy. Nasal polyps are more often associated with chronic sinusitis than alone.

Sargassum serratifolium is a sea horse of the brown algae plant that grows mainly in the south coast and Jeju, and the plant is a large brown algae with 1~4m in diameter, and its root is 4~5cm in diameter, has a cone shape and has rings. The stem is circumferentially short, divided into a number of central branches, and has a double serrated shape at the edge of the stem leaf. The effects of sawtooth plaque in nasal polyp disease have not been reported to date.

Korean Patent Registration No. 10-1783525 (registered on September 25, 2017)

In order to solve the above problems, the present invention provides a pharmaceutical composition for preventing or treating nasal polyp disease, or a health functional food composition for preventing or improving nasal polyp disease, containing the sawtooth capillary extract as an active ingredient.

The present invention provides a pharmaceutical composition or a health functional food composition for preventing recurrence of nasal polyp, containing a serpentine capillary extract as an active ingredient.

The pharmaceutical composition for preventing or treating nasal polyp disease according to the present invention may contain an extract of Sargassum serratifolium as an active ingredient.

The health functional food composition for preventing or improving nasal polyp disease according to the present invention may contain an extract of Sargassum serratifolium as an active ingredient.

The pharmaceutical composition for preventing recurrence of nasal polyps according to the present invention may contain an extract of Sargassum serratifolium as an active ingredient.

The health functional food composition for preventing recurrence of nasal polyps according to the present invention may contain an extract of Sargassum serratifolium as an active ingredient.

The extract of Sargassum serratifolium according to the present invention has antioxidant and anti-inflammatory activity and can be used as a pharmaceutical composition and health functional food composition for preventing, improving or treating nasal polyp disease, and effectively preventing and improving nasal polyp disease by ingesting it Or it can be cured.

In addition, the sawtooth capillary extract according to the present invention has the effect of inhibiting the expression of fibrosis-inducing factors and inhibiting the production of vascular endothelial growth factors, and thus can be utilized as a pharmaceutical composition and a health functional food composition for preventing nasal polyp recurrence, and using this It is possible to effectively prevent recurrence of cost after cost elimination surgery.

1 is a graph of the change of reactive oxygen species (ROS) according to the ethanol extract treatment of the sawtooth hatch according to an experimental example of the present invention.
Figure 2 is a graph of the change in nitrogen oxide (NO) according to the ethanol extract treatment of the sawtooth hatch according to an experimental example of the present invention.
Figure 3 is a graph of the change of prostaglandin E ₂ (PGE ₂ ) according to the ethanol extract treatment of sawtooth hatban according to an experimental example of the present invention.
Figure 4 shows the expression level of fibrosis-related factors according to the ethanol extract treatment of sawtooth hatch according to an experimental example of the present invention.
Figure 5 shows the expression level of vascular endothelial growth factor (VEGF) according to the ethanol extract treatment of the serrated capillary according to an experimental example of the present invention.

Hereinafter, the present invention will be described in detail.

The present inventors have completed the present invention by confirming the antioxidant, anti-inflammatory and anti-fibrotic activity in the ethanol extract prepared by using an aqueous ethanol solution as an extraction solvent.

In the present specification, "Sargassum serratifolium" is a sea horse of the brown algae plant that grows mainly in the south coast and Jeju, and the plant is a large brown algae of 1 to 4 m, and the root is 4 to 5 cm in diameter and has a cone shape and rings. There is. The stem is circumferentially short, divided into a number of central branches, and has a double serrated shape at the edge of the stem leaf.

In the present specification, the term "extract" refers to a substance obtained by extracting a component of a natural substance regardless of an extraction method, an extraction solvent, an extracted component, or a form of an extract, and after extracting a substance obtained by extracting a component of a natural substance, Any material that can be obtained by processing or processing by a method may be included.

In the present specification, "nasal polyp" refers to a benign edema mucosa in the shape of a grape cluster derived from the middle nasal passages (middle nose) protruding into the nasal cavity, and is a chronic inflammatory disease whose cause is not clearly known.

In the present specification, “prevention” refers to any action that inhibits the occurrence of or delays the onset of at least one symptom of a nasal polyp disease or the disease by administration of the pharmaceutical composition or health functional food composition according to the present invention. .

In the present specification, the term "treatment" refers to any action that improves or beneficially changes the symptoms of nasal polyp disease or at least one symptom of the disease by administration of the pharmaceutical composition according to the present invention. it means.

In the present specification, the term "improvement" refers to a nasal polyp disease or at least one symptom of the disease by ingestion of the health functional food composition according to the present invention to improve or beneficially change the symptoms such as alleviation, reduction, or disappearance. It means all actions.

In the present specification, “pharmaceutical composition” means a composition administered for a specific purpose, and for the purposes of the present invention, it is administered to prevent, treat, or prevent recurrence of at least one symptom of a nasal polyp disease or the disease. .

In this specification, the term "health functional food composition" is a food manufactured and processed using raw materials or ingredients that have useful functions for the human body. In addition to supplying nutrition, the term "health functional food composition" It means food and can be used interchangeably with terms known in the art such as functional food.

The present invention provides a pharmaceutical composition for preventing or treating nasal polyp disease containing an extract of Sargassum serratifolium as an active ingredient.

In the pharmaceutical composition according to the present invention, the sawtooth capillary extract may be extracted using a C1 to C4 alcohol or an aqueous solution thereof as a solvent. For example, methanol, propanol, butanol, or an aqueous solution thereof may be included as the solvent, preferably 60 to 80% by weight, more preferably 70% by weight of an aqueous ethanol solution, but is not limited thereto.

In the pharmaceutical composition according to the present invention, the sawtooth capillary extract may inhibit the production of one or more selected from the group consisting of reactive oxygen species (ROS), nitric oxide (NO), and prostaglandin E ₂ (PGE ₂ ).

ROS (reactive oxygen species; below, ROS) is a reactive molecule which chemically, including oxygen, superoxide radicals (superoxide radical, O ₂ ^-) hydroxy radical, hydrogen peroxide _{(hydrogenperoxide, H 2 O 2)} , ( It may contain hydroxy radical, ㆍOH), etc., and may cause oxidative stress in the body due to its high reactivity, and may cause and worsen inflammatory diseases such as nasal polyp disease.

According to an experimental example of the present invention, ROS increased when inflammation was induced by treatment with lipopolysaccharide (hereinafter, LPS), but ROS was significantly decreased when the LPS and sawtooth ethanol extract were treated in parallel. In particular, it was found that ROS significantly decreased as the treatment concentration of the ethanol extract of Sawtooth Hatus increased.

Further, the nitric oxide (nitric oxide; hereinafter, NO) and prostaglandin E _2; A may be generated excess by (prostaglandin E ₂ or less, PGE ₂₎ is a pro-inflammatory substances such as LPS or inflammation inducing cytokines, excess generation NO And PGE ₂ may cause problems such as tissue damage caused by an inflammatory reaction.

According to an experimental example of the present invention, the production of NO or PGE ₂ was significantly increased in the group treated with LPS alone, and the production of NO or PGE _{2 in} the group treated with the ethanol extract of LPS and serrations alone was treated with LPS alone. It was found to decrease in a concentration-dependent manner compared to the group.

That is, since the serrated capillary extract according to the present invention has an inhibitory effect on the production of reactive oxygen species (ROS), nitric oxide (NO) and prostaglandin E ₂ (PGE ₂ ), it is an effective pharmaceutical composition for the prevention or treatment of nasal polyp disease. Can be used. In addition, it may be effective in the prevention or treatment of not only the nasal polyp disease, but also a disease accompanying nasal polyp, such as sinusitis (sinusitis). More details will be described later in the following experimental examples.

The present invention provides a pharmaceutical composition for preventing recurrence of nasal polyps containing an extract of Sargassum serratifolium as an active ingredient.

In the pharmaceutical composition according to the present invention, the nasal polyp disease is an inflammatory disease having a high probability of recurrence, and the composition can prevent recurrence by inhibiting the remodeling of the nasal polyp after surgery to remove the nasal polyp.

In the pharmaceutical composition according to the present invention, the sawtooth capillary extract is selected from the group consisting of type 1 collagen, fibronectin, and α-smooth muscle actin (hereinafter, α-SMA). It is possible to inhibit the expression of one or more fibrosis inducing factors, and suppress the production of vascular endothelial growth factor (VEGF). According to an experimental example of the present invention, it was found that the expression of type 1 collagen, fibronectin, and α-SMA protein increased by TGF-β1 was significantly reduced by the ethanol extract of serrations, and the expression of VEGF was also an ethanol extract of serrations and Was found to decrease in a concentration-dependent manner. That is, because the serrated capillary extract according to the present invention has an effect of inhibiting the expression of fibrosis-inducing factors and inhibiting the production of vascular endothelial growth factor, it can be used as an effective pharmaceutical composition for preventing recurrence of nasal polyps. More details will be described later in the following experimental examples.

The pharmaceutical composition according to the present invention can be prepared according to a conventional method in the pharmaceutical field.

The pharmaceutical composition according to the present invention may be blended with an appropriate pharmaceutically acceptable carrier according to the above formulation, and further includes excipients, diluents, dispersants, emulsifiers, buffers, stabilizers, binders, disintegrants, solvents, etc., if necessary. It can be manufactured. The term "pharmaceutically acceptable" means that it is not toxic to cells or humans exposed to the pharmaceutical composition, and the appropriate carrier, etc., does not inhibit the activity and properties of the Sawtooth capillary extract according to the present invention. It may be selected differently depending on the form and formulation.

The pharmaceutical composition according to the present invention may be applied in any dosage form, and more particularly, may be formulated and used in parenteral dosage forms of oral dosage forms, external preparations, suppositories, and sterile injectable solutions according to conventional methods.

Among the oral dosage forms, the solid dosage form may be in the form of tablets, pills, powders, granules, capsules, etc., and at least one excipient such as starch, calcium carbonate, sucrose, lactose, sorbitol, mannitol, cellulose, gelatin, etc. It can be prepared by mixing, and in addition to simple excipients, lubricants such as magnesium stearate and talc may also be included. In addition, in the case of the capsul formulation, in addition to the above-mentioned substances, a liquid carrier such as fatty oil may be further included.

Among the oral dosage forms, liquid dosage forms correspond to suspensions, liquid solutions, emulsions, syrups, and the like.In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweetening agents, fragrances, preservatives, etc. may be included have.

The parenteral formulation may include a sterilized aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a lyophilized formulation, and a suppository. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, etc. may be used as the non-aqueous solvent and suspension. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used. The present invention is not limited thereto, and any suitable agent known in the art may be used.

In addition, the pharmaceutical composition according to the present invention may further include calcium or vitamin D ₃ to improve therapeutic efficacy.

In the pharmaceutical composition according to the present invention, the pharmaceutical composition may be administered in a pharmaceutically effective amount. The "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment and not cause side effects.

The effective dosage level of the pharmaceutical composition is the purpose of use, the patient's age, sex, weight and health condition, the type of disease, the severity, the activity of the drug, the sensitivity to the drug, the method of administration, the administration time, the administration route and the rate of excretion, the treatment It may be determined differently depending on the duration, factors including drugs used in combination or concurrently and other factors well known in the medical field. For example, although not constant, generally 0.001 to 100 mg/kg, preferably 0.01 to 10 mg/kg may be administered once to several times a day. The above dosage does not in any way limit the scope of the present invention.

The pharmaceutical composition according to the present invention can be administered by an appropriate route of administration according to the form of the formulation, and can be administered through various routes, either oral or parenteral, as long as it can reach the target tissue. The method of administration is not particularly limited and may be administered by conventional methods such as, for example, oral, rectal or intravenous, intramuscular, subcutaneous, intrabronchial inhalation, intrauterine dura mater or intracere-broventricular injection. .

The pharmaceutical composition according to the present invention may be used alone to prevent, treat or prevent recurrence of nasal polyp disease, or may be used in combination with surgery or other drug treatment.

The present invention provides a health functional food composition for preventing or improving nasal polyp disease containing an extract of Sargassum serratifolium as an active ingredient.

The sawtooth capillary extract can inhibit the production of one or more selected from the group consisting of reactive oxygen species (ROS), nitric oxide (NO), and prostaglandin E ₂ (PGE ₂ ), so it is effective in preventing or improving nasal polyp disease. It can be used as a nutraceutical composition.

In addition, the present invention provides a health functional food composition for preventing recurrence of nasal polyps containing an extract of Sargassum serratifolium as an active ingredient.

The sawtooth capillary extract is a type 1 collagen (Type 1 collagen), fibronectin (fibronectin) and α-smooth muscle actin (α-smooth muscle actin; hereinafter, α-SMA) selected from the group consisting of the expression of one or more fibrosis inducing factors selected from the group consisting of It can inhibit, and can inhibit the production of vascular endothelial growth factor (VEGF), it can be used as a health functional food composition effective in preventing nasal polyp recurrence.

In the health functional food composition according to the present invention, the health functional food may be prepared as a powder, granule, tablet, capsule, syrup or beverage, and there is no limitation on the form that the health functional food can take. It can include all foods of meaning. For example, beverages and various drinks, fruits and processed foods thereof (canned fruit, jam, etc.), fish, meat and processed foods thereof (ham, bacon, etc.), bread and noodles, cookies and snacks, dairy products (butter, cheese, etc.) ), and the like, and may include all functional foods in the usual sense. It may also include food used as feed for animals.

The health functional food composition according to the present invention may be prepared further comprising a food pharmaceutically acceptable food additive and other appropriate auxiliary ingredients commonly used in the art. For example, flavoring agents, natural carbohydrates, sweetening agents, vitamins, electrolytes, colorants, pectic acids, alginic acids, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents, etc. I can. In particular, as the natural carbohydrates, monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol, and erythritol may be used. , As the sweetener, natural sweeteners such as taumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame may be used.

The health functional food composition according to the present invention has the advantage of not having side effects that may occur when taking the drug for a long period of time, unlike general drugs, and it is excellent in portability, preventing, improving or recurring nasal polyp disease. It can be taken as a preventive supplement.

Hereinafter, examples will be described in detail to aid understanding of the present invention. However, the following examples are for illustrative purposes only, and the scope of the present invention is not limited to the following examples. The embodiments of the present invention are provided to more completely explain the present invention to those of ordinary skill in the art.

<Example 1> Preparation of ethanol extract (NP-0146) of sawtooth hatch

After collecting the brown algae in the vicinity of Seogwipo, Jeju, the salt, attached plants, and sand adhered to the surface of the serrated hat are removed through washing and stored at -20°C.

The frozen sample before extraction was freeze-dried under reduced pressure and homogenized using a grinder. The dried powder was extracted by sonicating for 1 hour in 70% ethanol (EtOH, 1:10 w/v). After repeating the extraction process 5 times, the extract was evaporated under vacuum, which was dissolved in dimethyl sulfoxide (DMSO) before use in the experiment.

<Experimental Example 1> Confirmation of the inhibitory effect on the production of reactive oxygen species (ROS) of the ethanol extract of sawtooth hatch

, Hydrogen peroxide (hydrogenperoxide, H ₂ O ^- superoxide radicals (superoxide radical, O ₂₎ that is generated when the handle; (hereinafter, LPS lipopolysaccharide) is described in Example 1 a saw-tooth Sargassum ethanol extract prepared in accordance with the lipopolysaccharide in fibroblasts ₂ ), and the effects of hydroxy radical (ㆍOH) on the generation of reactive oxygen species (ROS) were investigated.

In order to measure ROS, 2,7-dichlorohydrofluorescin diacetate (DCFDA) is oxidized by ROS, resulting in fluorescence of 2,7-dichlorofluorescein (2,7-dichlorofluorescein, DCF). ) Was used as a fluorescence assay. After treating the RAW 264.7 cells with CM-H2DCFDA (General Oxidative Stress Indicator) at a concentration of 5 μM for 30 minutes, the ethanol extract of serpentine spots was treated for 30 minutes. After 24 hours of stimulation with 1 μg/mL of LPS, ROS was measured at 492/525 nm.

1 is a graph of the change of reactive oxygen species (ROS) according to the ethanol extract treatment of the sawtooth hatch according to an experimental example of the present invention.

Referring to Figure 1, compared to the control group treated with LPS alone, reactive oxygen species (hereinafter, ROS) significantly increased, and when treated in parallel with LPS and sawtooth capillary ethanol extract (NP0146), generally LPS alone ROS was significantly decreased compared to the treatment group. In particular, it was found that when the concentrations of 100, 200, and 300 μg/mL of the ethanol extract were treated, the ROS significantly decreased as the concentration of the ethanol extract increased.

<Experimental Example 2> Confirmation of the inhibitory effect of nitric oxide (NO) production of ethanol extract of sawtooth hatch

After culturing RAW 264.7 cells in a 24-well plate, treated with 0, 100, 200, 300 µg/mL and reacted for 30 minutes with the ethanol extract of Sawtooth Hatchery, 1 µg/mL LPS, and cultured for 24 hours. 150 µl of the culture solution and 20 µl of a grease reagent kit were mixed, reacted at room temperature for 30 minutes, and absorbance was measured at 548 nm.

Figure 2 is a graph of the change in nitrogen oxide (NO) according to the ethanol extract treatment of the sawtooth hatch according to an experimental example of the present invention.

Referring to Figure 2, compared to the control group treated with LPS alone, the production of nitrogen oxide (hereinafter, NO) was significantly increased, and in the group treated with the ethanol extract of LPS and serrations, the production of NO was LPS alone treatment group. Compared to the concentration-dependent decrease, in particular, when the concentration of the ethanol extract of Sawtooth Hatcheri was 200 μg/mL or more, NO production was significantly reduced.

<Experimental Example 3> Prostaglandin E2 (Prostaglandin E) of ethanol extract of sawtooth hatch ₂ , PGE ₂ ) Confirmation of production inhibition effect

Prostaglandin E ₂ (PGE _2, R&D Inc., Minneapolis, MN, USA) was treated according to the suggested method using an ELISA kit, and then absorbance was measured at 405 nm.

Figure 3 is a graph of the change of prostaglandin E ₂ (PGE ₂ ) according to the ethanol extract treatment of sawtooth hatban according to an experimental example of the present invention.

3, compared to the control group, the production of prostaglandin E ₂ (hereinafter, PGE ₂ ) was significantly increased in the group treated with LPS alone, and the production of PGE _{2 in} the group treated with the ethanol extract of LPS and serration Compared to the LPS alone treatment group, it was found to decrease in a concentration-dependent manner. In particular, when the concentration of the ethanol extract of Sawtooth Hatcheri was 200 µg/mL or more, PGE ₂ production was significantly reduced.

<Experimental Example 4> Confirmation of the effect of inhibiting the expression of factors related to fibrosis by ethanol extract of sawtooth hatch

In order to confirm the presence or absence of fibrosis induction of cost (nose polyp) fibroblasts by transforming growth factor beta 1 (TGF-β1) and the effect of suppressing fibrosis by ethanol extract of serrations, a fibrosis inducing gene The expression levels of type 1 collagen, fibronectin and α-smooth muscle actin (hereinafter, α-SMA) proteins were confirmed.

Figure 4 shows the expression level of fibrosis-related factors according to the ethanol extract treatment of sawtooth hatch according to an experimental example of the present invention.

Referring to FIG. 4, it was found that the expression of type 1 collagen, fibronectin, and α-SMA protein increased by TGF-β1 was significantly reduced by the ethanol extract of serrations.

<Experimental Example 5> Confirmation of the effect of inhibiting vascular endothelial growth factor (VEGF) production in nasal polyp tissues by ethanol extract of serrated capillary spot

It has been reported that high vascular endothelial growth factor (VEGF) levels in nasal polyps can promote nasal polyp formation by activating VEGF receptors and downstream signaling pathways (Azizzadeh Delshad A, Jalali Nadoushan M, Davati A, Rostami A: Expression of Vascular Endothelial Growth Factor in Nasal Polyp and Chronic Rhinosinusitis.Iran J Pathol. 2016;11(3):231-237). Therefore, in order to find a material capable of inhibiting the formation of nasal polyps by inhibiting the production of VEGF, an ex vivo method of treating human nasal polyp tissue with an ethanol extract of serrated hatch was investigated.

The nasal polyp tissue was cut into 2-3 mm ³ , washed 3 times with phosphate buffered saline, 10% fetal bovine serum (FBS) and 1% 10,000 units/ml penicillin, 1% 10,000 μg/ mL streptomycin solution was added. The VEGF expression was measured after treatment with ethanol extract (25, 50, 100 µg/mL) of serrated hatch on the nasal polyp tissue for 24 hours.

Figure 5 shows the expression level of vascular endothelial growth factor (VEGF) according to the ethanol extract treatment of the serrated capillary according to an experimental example of the present invention.

Referring to FIG. 5, it was found that the expression of VEGF was decreased in a concentration-dependent manner by treatment with the ethanol extract of serrated hatchery.

As described above, specific parts of the present invention have been described in detail, and for those of ordinary skill in the art, it is obvious that these specific techniques are only preferred embodiments, and the scope of the present invention is not limited thereby. Do. That is, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims (9)

A pharmaceutical composition for preventing or treating nasal polyp disease containing an extract of Sargassum serratifolium as an active ingredient. The method of claim 1,
The sawtooth capillary extract,
A pharmaceutical composition for preventing or treating nasal polyp disease, characterized in that it is extracted using C1 to C4 alcohol or an aqueous solution thereof as a solvent. The method of claim 1,
The sawtooth capillary extract,
A pharmaceutical composition for preventing or treating nasal polyp disease, characterized in that it inhibits the production of one or more selected from the group consisting of reactive oxygen species (ROS), nitric oxide (NO) and prostaglandin E ₂ (PGE ₂ ). A pharmaceutical composition for preventing recurrence of nasal polyps containing an extract of Sargassum serratifolium as an active ingredient. The method of claim 4,
The composition,
After surgery to remove nasal polyps, a pharmaceutical composition for preventing recurrence of nasal polyps, characterized in that to prevent recurrence by inhibiting remodeling of nasal polyps. The method of claim 4,
The sawtooth capillary extract,
Cost characterized by inhibiting the expression of one or more fibrosis inducing factors selected from the group consisting of Type 1 collagen, fibronectin and α-smooth muscle actin (α-SMA) Pharmaceutical composition for preventing species recurrence. The method of claim 4,
The sawtooth capillary extract,
A pharmaceutical composition for preventing recurrence of nasal polyps, characterized in that it inhibits the production of vascular endothelial growth factor (VEGF). A health functional food composition for preventing or improving nasal polyp disease, containing an extract of Sargassum serratifolium as an active ingredient. A health functional food composition for preventing recurrence of nasal polyps containing an extract of Sargassum serratifolium as an active ingredient.

Images